Cargando…
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19
Autores principales: | Bozkurt, Biykem, Kovacs, Richard, Harrington, Bob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Churchill Livingstone
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234783/ https://www.ncbi.nlm.nih.gov/pubmed/32439095 http://dx.doi.org/10.1016/j.cardfail.2020.04.013 |
Ejemplares similares
-
ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison
por: Behnoush, Amir Hossein, et al.
Publicado: (2022) -
The AHA/ACC/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention
por: Abovich, Arielle, et al.
Publicado: (2023) -
ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Chronic Coronary Disease
por: Winchester, David E., et al.
Publicado: (2023) -
Society for Cardiovascular Magnetic Resonance perspective on the ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 multi-modality appropriate use criteria for the detection and risk assessment of chronic coronary disease
por: Bandettini, W. Patricia, et al.
Publicado: (2023) -
AHA/ACC/Multisociety Cholesterol Guidelines:
highlights
por: Jialal, Ishwarlal, et al.
Publicado: (2019)